| __timestamp | Grifols, S.A. | Madrigal Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 660772000 | 15746000 |
| Thursday, January 1, 2015 | 736435000 | 13392000 |
| Friday, January 1, 2016 | 775266000 | 9290000 |
| Sunday, January 1, 2017 | 860348000 | 7672000 |
| Monday, January 1, 2018 | 814775000 | 15293000 |
| Tuesday, January 1, 2019 | 942821000 | 22648000 |
| Wednesday, January 1, 2020 | 985616000 | 21864000 |
| Friday, January 1, 2021 | 1061508000 | 37318000 |
| Saturday, January 1, 2022 | 1190423000 | 48130000 |
| Sunday, January 1, 2023 | 1254234000 | 108146000 |
Infusing magic into the data realm
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Grifols, S.A. and Madrigal Pharmaceuticals, Inc. have taken distinct paths in optimizing these costs. Grifols, a global leader in plasma-derived medicines, has seen its SG&A expenses rise steadily, peaking at approximately 1.25 billion in 2023, a 90% increase from 2014. This growth reflects its expansive global operations and strategic investments.
Conversely, Madrigal Pharmaceuticals, a smaller player focused on innovative therapies, has maintained a more conservative SG&A growth. From 2014 to 2023, their expenses increased by about 587%, reaching 108 million. This sharp rise, however, is from a much smaller base, indicating strategic scaling efforts.
The contrasting strategies highlight the balance between growth and cost management, offering valuable insights for investors and industry analysts.
AstraZeneca PLC and Grifols, S.A.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: argenx SE vs Madrigal Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Bio-Techne Corporation and Grifols, S.A.
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Madrigal Pharmaceuticals, Inc.
Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs Opthea Limited Trends and Insights
Selling, General, and Administrative Costs: Madrigal Pharmaceuticals, Inc. vs Verona Pharma plc
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Viking Therapeutics, Inc.
Madrigal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
Madrigal Pharmaceuticals, Inc. or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and Opthea Limited
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and Axsome Therapeutics, Inc.
Breaking Down SG&A Expenses: Grifols, S.A. vs Amphastar Pharmaceuticals, Inc.